Bioengineering: Doing without donors | Nature
Featured in NATURE
28 SEPTEMBER 2017 | VOL 549 | NATURE
Each year, at about 13,000 collection centres worldwide, phlebotomists stick needles in the veins of healthy volunteers and amass in excess of 110 million donations of blood. The volume collected is enough to fill 20 Olympic-sized swimming pools — but it’s nowhere near to meeting the medical demand for whole blood or its components. To fill the gap, an enterprising group of stem-cell biologists and bioengineers hopes to produce a safe, reliable and bottomless supply of on-demand blood substitutes in the laboratory.
QUICK LINKS
ABOUT US
KaloCyte was founded by a distinguished team of researchers in physiology, bioengineering, and trauma care and is poised to deliver ErythroMer, a dried, bio-inspired artificial red blood cell, to market. ErythroMer is envisioned for use when stored red blood cells are unavailable, undesirable or in short supply. KaloCyte is supported by nearly $20M in federal grants and investor funding.